Switch Therapeutics
South San Francisco, US · Founded 2020 · Delaware corporation · 9 known investors
Switch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.
AI & Machine LearningBiotechDeep TechMedical Devices
Founders & leadership
Switch Therapeutics was founded in 2020 by Si-Ping Han and Deepshikha Datta.
SH
Si-Ping HanSecretary
DD
Deepshikha DattaChief Executive Officer and President
Board
KZ
Kevin ZhangBoard director
AI
DM
Dylan MorrisBoard director
Investors · 9
Bold Capital PartnersSanta Monica
CRV (Charles River Ventures)San Francisco · $250K – $5M
FREEFLOWBerkeley
Global BrainTokyo · $100K – $184M
Ono Venture Investment, Inc.South San Francisco
Upfront VenturesLos Angeles · $1M – $10M
Digitalis VenturesreportedNew York · $100K – $10M
Dolby Family VenturesreportedSan Francisco
UCB VenturesreportedBrusselsvia Alicia Irurzun-Lafitte · board
Reported raises · per SEC filings
Form D private placements$23.3M disclosed across 1 round · 2022
▶$23.3MraisedNov 2022 · 15 investors · OtherRule 506(b)
▶$23.3MraisedNov 2022 · 15 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Kevin ZhangDirector
- Alicia Irurzun-LafitteDirector
- Dylan MorrisDirector
- Si-Ping HanExecutive Officer
- Deepshikha DattaExecutive Officer, Director
- Offering amount
- $36M
- Amount sold
- $23.3M
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 8
by search overlapSionnatx34 shared keywordsSionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.
Sirnaomics30 shared keywordsSirnaomics is an RNA therapeutics company developing RNA interference (RNAi) drugs using its proprietary PNP (Peptide Nanoparticle) delivery platform for extra-hepatic delivery and its GalAHead technology for controlling therapeutic duration. Its pipeline spans oncology, regenerative and aesthetic medicine, and cardiovascular and metabolic diseases.
Ronatherapeutics30 shared keywordsRona Therapeutics develops siRNA-based therapeutics using its GAIA platform to target metabolic and cardiovascular conditions including hypertriglyceridemia, obesity, ASCVD, and MASH. Its pipeline includes APOC3, INHBE, PCSK9-Lp(a), and angiotensinogen-targeting candidates for patients with cardiovascular and metabolic diseases.
Syrna Therapeutics26 shared keywordsSyrna Therapeutics is a biotech company developing small-molecule covalent translation inhibitors that bind and modify structured domains in the mRNA of disease-causing proteins to block their expression. It uses a 3D structure-guided drug discovery platform, with lead programs in immunology and neurodegeneration and a broader pipeline spanning metabolic disease and oncology.
Siriusrna26 shared keywordsSirius is a biotech company developing RNAi-based therapies focused on cardiovascular diseases for global markets. It applies RNA interference technology to create new treatment options for patients.
Bioworld23 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Serna Bio19 shared keywordsSerna builds a platform to unlock the transcriptome as a drug target for drug discovery. The company integrates technology and biology to change drug discovery processes.
Neurona Therapeutics18 shared keywordsNeurona is a clinical-stage biotherapeutics company developing allogeneic, off-the-shelf regenerative neural cell therapies that integrate into neural circuits to treat chronic neurological disorders. Its pipeline includes neuronal, glial, and gene-edited cell therapy candidates led by NRTX-1001, an inhibitory neuron therapy for epilepsy.</parameter>
<parameter name="founders">[]
Companies competing with Switch Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Switch Therapeutics do?
- Switch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.
- Who founded Switch Therapeutics?
- Switch Therapeutics was founded by Si-Ping Han, Deepshikha Datta in 2020.
- Who are Switch Therapeutics's investors?
- Switch Therapeutics's investors include Bold Capital Partners, CRV (Charles River Ventures), FREEFLOW, Global Brain, Ono Venture Investment, Inc., Upfront Ventures, Digitalis Ventures, Dolby Family Ventures and 1 more.
- How much funding has Switch Therapeutics raised?
- Switch Therapeutics has disclosed $23.3M raised across 1 round.
- Where is Switch Therapeutics headquartered?
- Switch Therapeutics is headquartered in South San Francisco, US.